The collaboration with Onkos is paving the way for further growth in the US
The collaboration with Onkos is truly starting to pay off. Not only has Onkos recruited a number of well reputed hospitals (among which Emory Healthcare, USC Keck Medical Center, and Duke Health) to the OPRA™ network, these hospitals are now performing their first surgeries with the OPRA™ Implant System and their respective patient treatment plans, and have new patients in the pipeline.
Despite the ongoing pandemic, and the subsequent current restrictions placed on elective surgery, these first surgeries have been successfully performed, and further treatments scheduled. Integrum is very pleased with the recent progress made by Onkos, and we are very much looking forward to a continued expansion of our collaboration.
About Onkos Surgical
Onkos Surgical was founded in 2015, with a singular focus on bringing innovation to musculoskeletal oncologists and the patients they care for. Built on a digital platform, Onkos is an emerging leader in the field of personalized orthopaedics. With expertise in personalized surgical planning, 3D modeling and the latest advancements in 3D printing, the company has developed a suite of products designed to reduce complexity and address the clinical challenges associated with tumor and complex orthopedic revision surgery.
Today, Onkos Surgical covers the entire US market, with a special focus on leading university hospitals in the orthopaedic oncology field. In Onkos’ network there are 115 independent sales representatives serving hospitals across the country. www.onkossurgical.com.
Says Maria Lopez, CEO of Integrum “Given the ongoing pandemic, the rapid progress of the collaboration with Onkos is encouraging, and will both in the short term, but especially in the long term, have significant bearing on the revenue growth in the US”.
This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-02-2021 08:45 CET. Integrum is listed on Nasdaq First North in Stockholm. Erik Penser is the Company's Certified Adviser.
For further information, please contact:
Maria Lopez, CEO
Cell. +46 (0) 708-46 10 69
Erik Penser Bank AB
Tel. +46 (0) 8 463 8000
Integrum AB is a publicly-traded company (INTEG B: Nasdaq First North exchange) based outside of Gothenburg, Sweden, with a US subsidiary in San Francisco, CA. Since 1990, osseointegration, the science behind the OPRATM Implant System, has been helping individuals with amputations enjoy a dramatically improved quality of life. Thorough surgical experience gained over more than three decades, from 500 surgeries, in 14 countries, has led to the development of Integrum’s system for bone- anchored prostheses – a vastly superior alternative to the traditionally used socket prosthesis.
The OPRA™ Implant System is the only FDA approved medical device for above- knee, bone-anchored prosthetics available in the US. More information on the company and its innovative solutions for amputees can be found at www.integrum.se.
Brighter AB (publ) Year-end report 2020
Operating result for the period amounted to SEK -101,604 thousand (-35,029). Brighter contributed SEK -81,472 thousand to the operating result and the rest refers to Camanio and Pink Nectarine Health which were acquired in Q4 2019 and Q1 2020. Among the reasons for the higher loss were additions of...
First Non-Cancer Scalp Cooling Study for the Prevention of Chemotherapy-induced Hair Loss in Pediatric Patients
An observational, prospective pilot study will see the use of a Paxman Scalp Cooling System for the first time in such research.The research “Pilot Study of Cold Cap Therapy for Prevention of Hair loss in Pediatric Patients Receiving Chemotherapy for Non-Malignant Indications” is not only the first...
Första skalpkylningsstudien med icke-cancerpatienter för att motverka cellgiftsinducerat håravfall hos barn och unga
En pilotstudie i form av en prospektiv observationsstudie kommer att utgöra första gången som Paxman Scalp Cooling System används inom det här forskningsområdet.Utöver att vara den första studien då Paxmans skalpkylningssystem används av en patientgrupp som består av barn och unga så är studien “Pil...
Announcement from FRISQ's annual general meeting
Adoption of the income statement and the balance sheetThe AGM resolved to adopt the income statement and the balance sheet in FRISQ and the consolidated income statement and the consolidated balance sheet.Allocation of profitThe AGM resolved that no dividend would be paid to the shareholders and tha...